July 18, 2025

Tislelizumab Outcomes Linked to PD-L1 Method

Researchers compare Tumor Area Positivity score and Combined Positive Score for programmed death-ligand 1 expression in gastric and esophageal cancers

The Pathologist

July 28, 2025

New Celiac Disease Program Excels at Patient-Centered Care

At Mount Sinai's new Celiac Disease Program, patients can meet with a gastroenterologist, GI nutrition physician, health psychologist, and dietitian specializing in celiac disease. That integrated approach ensures patients’ clinical, dietary, and social-emotional needs are met.

Mount Sinai New York

July 24, 2025

Perioperative Therapy With Durvalumab Plus FLOT: A Potential New Standard of Care in Gastric or Gastroesophageal Junction Cancer

In patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma, perioperative treatment with the checkpoint inhibitor durvalumab in combination with standard chemotherapy signif...

The ASCO Post

July 22, 2025

Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer

Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluor...

The ASCO Post

September 28, 2023

Does Colon Tumor Location Play a Role in Metastasis and Survival?

A recent study examined survival outcomes among patients with right-sided vs left-sided colorectal tumors that had metastasized to the liver. The findings provide insight into the unique biology of ri...

The ASCO Post

November 13, 2023

FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer

On November 8, the FDA approved an anti-VEGF tyrosine kinase inhibitor for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based che...

The ASCO Post

June 13, 2024

ADA calls for increased resources for Indian Health Service

The ADA is advocating for increased funding and resources for the Indian Health Service.

ADA News

July 19, 2024

Interaction of the Gut Microbiome With Cancer Treatment

Research finds that the gut microbiome has a significant impact on cancer pathogenesis and treatment responses, opening new avenues for improving cancer therapy outcomes.

JADPRO

March 24, 2023

Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber

The rise of colorectal cancer in those under 50 has spurred reevaluation of screening guidelines. Dr. Benjamin Schlechter is pioneering studies to explore novel treatment options, including next-generation immunotherapy drugs and CAR T-cell therapy, showing promising clinical activity.

The ASCO Post